1. The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients
- Author
-
Yesim Parman, Vuslat Yilmaz, Güher Saruhan-Direskeneli, Hacer Durmus, Piraye Oflazer, Fikret Aysal, Erdem Tüzün, Ozlem Gungor-Tuncer, and Feza Deymeer
- Subjects
0301 basic medicine ,Adult ,Male ,Adolescent ,medicine.medical_treatment ,Immunology ,CD38 ,CD19 ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Myasthenia Gravis ,medicine ,Immunology and Allergy ,Humans ,B-cell activating factor ,Child ,B cell ,Aged ,B-Lymphocytes ,biology ,business.industry ,Immunosuppression ,Middle Aged ,medicine.disease ,Myasthenia gravis ,Pathophysiology ,030104 developmental biology ,medicine.anatomical_structure ,Treatment Outcome ,Neurology ,biology.protein ,Female ,Neurology (clinical) ,Antibody ,business ,030217 neurology & neurosurgery ,Biomarkers ,Immunosuppressive Agents - Abstract
B cells play a major role in the pathophysiology of myasthenia gravis (MG) with their ability to produce disease specific, pathogenic antibodies. However, their status during disease development and follow-up stages of the disease in the peripheral blood may need further studies to determine useful markers. In this study, we aimed to detect B cell associated factors concerning immunosuppressive treatment in generalized non-thymomatous MG patients. Although CD19(+) B cell distribution did not vary among disease subgroups, expressions of both CD38 and BAFFR were altered on B cells in MG patients under immunosuppressive therapy. Serum levels of BAFF were elevated in untreated MG patients as compared to treated MG patients and healthy controls. B cell activation factors may show profound alterations due to immunosuppression.
- Published
- 2020